Ihre E-Mail wurde erfolgreich gesendet. Bitte prüfen Sie Ihren Maileingang.

Leider ist ein Fehler beim E-Mail-Versand aufgetreten. Bitte versuchen Sie es erneut.

Vorgang fortführen?

Exportieren
Filter
  • Brietzke, Andreas  (3)
Medientyp
Verlag/Herausgeber
Sprache
Erscheinungszeitraum
  • 1
    Online-Ressource
    Online-Ressource
    Walter de Gruyter GmbH ; 2019
    In:  Current Directions in Biomedical Engineering Vol. 5, No. 1 ( 2019-09-01), p. 335-337
    In: Current Directions in Biomedical Engineering, Walter de Gruyter GmbH, Vol. 5, No. 1 ( 2019-09-01), p. 335-337
    Kurzfassung: On the protection of animals used for scientific purposes, the EU Parliament adopted Directive 2010/63/EU. The essential factor is the 3R principle: Replacement, Reduction and Refinement. In 2013, the third amendment to the German Animal Welfare Act was revised and adapted to the European Directive. The majority of animals in science are used in basic research, as well as in translational and applied research. In medical research, animal experimentation is conducted to clarify previously unknown life processes and basic biological relationships, in order to improve diagnostics and treatment of human diseases. Before an animal experiment can be performed, it must be reported to and approved by the responsible authorities. The planned research project must be justified scientifically, and it must be demonstrated that the personnel and spatial/ technical prerequisites are in place to successfully complete the project. If all conditions are met, the approval can be granted, but may be subject to conditions. The guiding principle of essentiality also affects the procedure of the experiments: The number of animals used and the pain, suffering and damage caused to these animals must be limited to what is absolutely necessary. In this context, the 3R principle has to be applied. To obtain reliable results, it is essential that the laboratory animals are in normal physiological conditions and free of pain and fear. Scientific interest and animal welfare are therefore not in opposition, but rather mutually dependent. In our GLP (Good Laboratory Practice) laboratory we test new drug release systems for different biomedical applications in rabbits after careful selection of the animal model. Stress during animal experiments must be avoided as far as possible. Providing pain-killers and ensuring the best possible husbandry and care conditions are crucial for the animal’s wellbeing and absence of pain and anxiety. In the present work we report our different experience in a GLPcertified biomaterial test laboratory.
    Materialart: Online-Ressource
    ISSN: 2364-5504
    Sprache: Englisch
    Verlag: Walter de Gruyter GmbH
    Publikationsdatum: 2019
    ZDB Id: 2835398-5
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 2
    Online-Ressource
    Online-Ressource
    Walter de Gruyter GmbH ; 2017
    In:  Current Directions in Biomedical Engineering Vol. 3, No. 2 ( 2017-09-26), p. 695-698
    In: Current Directions in Biomedical Engineering, Walter de Gruyter GmbH, Vol. 3, No. 2 ( 2017-09-26), p. 695-698
    Kurzfassung: For the development of intelligent implant systems hydrogels (HG) from crosslinked ionic liquids feature a high potential to be utilised as a drug depot. Biocompatibility of the HGs is one key prerequisite for biomedical applications. HGs were polymerised from a variety of different ionic monomers based on methacrylate, methacrylamide, styrene or vinyl imidazolium derivatives in aqueous solution. N,N'-methylenebisacrylamide was used as crosslinker. CellQuanti-Blue™ Cell Viability Assay Kit was implemented to proof viability of L929 mouse fibroblasts. The predominant part of the HG eluates generated only a marginal reduction of less than 15% cell viability at 100% eluate concentration. This underlines the excellent suitability of these HGs for biomedical applications and revealed some promising candidates for the development of drug depots for implants.
    Materialart: Online-Ressource
    ISSN: 2364-5504
    Sprache: Englisch
    Verlag: Walter de Gruyter GmbH
    Publikationsdatum: 2017
    ZDB Id: 2835398-5
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
  • 3
    Online-Ressource
    Online-Ressource
    Walter de Gruyter GmbH ; 2019
    In:  Current Directions in Biomedical Engineering Vol. 5, No. 1 ( 2019-09-01), p. 481-483
    In: Current Directions in Biomedical Engineering, Walter de Gruyter GmbH, Vol. 5, No. 1 ( 2019-09-01), p. 481-483
    Kurzfassung: Implants that feature a drug delivery system loaded with antifibrotic active drugs provide a promising approach to address postoperative complications caused by fibrosis. This study is intended to clarify whether Actinomycin D has an impact specifically on components of the extracellular matrix (ECM) and its formation in human primary fibroblasts of the Tenon capsule (hTF). Furthermore, the suitability of this agent in poly(N-vinylpyrrolidone)- poly(methylmethacrylate)(PVP-co-PMMA) as a drug delivery model is evaluated in drug incorporation and release studies. RT-qPCR revealed a significant downregulation of the fibrotic marker genes ACTA2, COL1A1 and FN1 in cells stimulated with TGF- β1 and additionally treated with Actinomycin D. However, these findings could only be confirmed on α- SMA protein level. collagen I and Fibronectin synthesis stayed unaffected. The diffusion based incorporation of Actinomycin D into the polymer model proved to be very effective. The release of the agent was retarded with a slightly prolonged kinetic. These findings make Actinomycin D a promising antifibrotic agent in ophthalmic implant surgery.
    Materialart: Online-Ressource
    ISSN: 2364-5504
    Sprache: Englisch
    Verlag: Walter de Gruyter GmbH
    Publikationsdatum: 2019
    ZDB Id: 2835398-5
    Bibliothek Standort Signatur Band/Heft/Jahr Verfügbarkeit
    BibTip Andere fanden auch interessant ...
Schließen ⊗
Diese Webseite nutzt Cookies und das Analyse-Tool Matomo. Weitere Informationen finden Sie auf den KOBV Seiten zum Datenschutz